Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$166.15 USD

166.15
4,722,495

-0.92 (-0.55%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $166.16 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?

Intuitive Surgical is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.

Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session.

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.

Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $166.61, moving +1.36% from the previous trading session.

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

Smart Beta ETF report for HDV

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Invesco S&P 500 Quality ETF (SPHQ) a Strong ETF Right Now?

Smart Beta ETF report for SPHQ

Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to Know

Johnson & Johnson (JNJ) concluded the recent trading session at $167.16, signifying a +0.78% move from its prior day's close.

JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab

The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs

LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.

Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

Smart Beta ETF report for DGRO

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly

Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.

Kinjel Shah headshot

J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?

We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.

J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC

The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.

Addex Stock Soars on Crucial Update From Indivior Research Deal

ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.

Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts

Johnson & Johnson (JNJ) closed the most recent trading day at $162.95, moving -1.01% from the previous trading session.

Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?

MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.

Should Invesco Large Cap Value ETF (PWV) Be on Your Investing Radar?

Style Box ETF report for PWV

J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa

The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.